# A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients

> **NCT06292923** · PHASE2 · RECRUITING · sponsor: **Tiziana Life Sciences LTD** · enrollment: 54 (estimated)

## Conditions studied

- Secondary Progressive Multiple Sclerosis

## Interventions

- **DRUG:** Foralumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06292923
- **Lead sponsor:** Tiziana Life Sciences LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-15
- **Primary completion:** 2025-11
- **Final completion:** 2025-11
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2025-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06292923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06292923, "A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06292923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*